<p>ProKidney Corp.（納斯達克代碼：PROK - 獲取免費報告）週四下跌了 5.5%。該公司的股價最低跌至$2.15，最後交易價為$2.1550。在午盤交易中，共交易了 358,174 股，較平均交易量 973,694 股下降了 63%。該股票此前收盤價為$2.28。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些股票分析師最近對 PROK 股票發表了評論。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 ProKidney 的 “賣出（d-）” 評級。HC Wainwright 在 12 月 16 日星期二的研究報告中開始覆蓋 ProKidney 股票。他們對該股票設定了 “買入” 評級和$12.00 的目標價。四位分析師給予該股票 “買入” 評級，一位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “持有”，平均目標價為$7.40。</p>
<p><strong>查看我們最新的 PROK 股票報告</strong></p>
<h2>ProKidney 股票表現</h2>
<p>該公司的 50 日移動平均價格為$2.34，200 日移動平均價格為$2.59。該公司的市值為 6.6032 億美元，市盈率為-3.99，貝塔值為 1.79。</p>
<p>ProKidney（納斯達克代碼：PROK - 獲取免費報告）最近於 11 月 10 日星期一發布了季度財報。該公司報告季度每股收益為（$0.12），符合分析師的共識預期（$0.12）。該業務在季度內的收入為 22 萬美元，而分析師預期為 4 萬美元。整體來看，分析師預計 ProKidney Corp.在本年度將發佈每股收益為-0.57。</p>
<h2>ProKidney 內部活動</h2>
<p>在相關消息中，董事 Brian Jg Pereira 於 11 月 13 日星期四出售了 502,136 股該公司的股票。股票以平均價格$2.37 出售，總價值為$1,190,062.32。此次出售已在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。41.49% 的股票由公司內部人士持有。</p>
<h2>機構投資者對 ProKidney 的看法</h2>
<p>機構投資者和對沖基金最近增加或減少了對該公司的持股。Zullo Investment Group Inc.在第三季度購買了 ProKidney 的新股份，價值$28,000。Catalyst Funds Management Pty Ltd 在第二季度收購了 ProKidney 的新股份，價值約$36,000。AQR Capital Management LLC 在第一季度將其在 ProKidney 的持股增加了 106.4%。AQR Capital Management LLC 現在擁有 52,570 股該公司的股票，價值$46,000，此前在上個季度又購買了 27,098 股。Jefferies Financial Group Inc.在第三季度收購了 ProKidney 的新股份，價值約$158,000。最後，Virtu Financial LLC 在第三季度收購了 ProKidney 的新股份，價值約$203,000。對沖基金和其他機構投資者持有該公司 51.59% 的股票。</p>
<h2>關於 ProKidney</h2>
<p>（獲取免費報告）</p>
<p>ProKidney, Inc.（納斯達克代碼：PROK）是一家臨牀階段的生物技術公司，專注於開發針對腎臟疾病的細胞治療。該公司的研究和開發活動集中在利用人源近端小管細胞來解決急性腎損傷（AKI）和慢性腎病（CKD）等疾病。通過針對腎臟損傷和功能障礙的基礎細胞機制，ProKidney 旨在提供超越當前支持性護理選項的新型再生醫學方法。</p>
<p>ProKidney 的主要項目利用專有方法分離和擴展腎上皮細胞，以創建可注射的治療產品。</p>
<h2>另請參閲</h2>
<ul>
<li>五隻我們更看好的股票，勝過 ProKidney</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行命令 14330：特朗普最大的一次</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 ProKidney 嗎？</h2>
<p>在考慮 ProKidney 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ProKidney 並不在名單上。</p>
<p>雖然 ProKidney 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PROK

<p>ProKidney Corp.（納斯達克代碼：PROK）股價下跌 5.5%，至 2.1550 美元，交易量較平均水平下降 63%。分析師的評級意見不一，Weiss Ratings 給出 “賣出” 評級，而 HC Wainwright 則給予 “買入” 評級，目標價為 12 美元。該股票的共識評級為 “持有”，平均目標價為 7.40 美元。ProKidney 報告的季度每股收益為（0.12 美元），收入為 22 萬美元。機構投資者持有 51.59% 的股份，公司專注於腎臟疾病的細胞治療</p>

<p>ProKidney Corp. (NASDAQ:PROK - Get Free Report) fell 5.5% on Thursday . The company traded as low as $2.15 and last traded at $2.1550. 358,174 shares were traded during mid-day trading, a decline of 63% from the average session volume of 973,694 shares. The stock had previously closed at $2.28.</p>
<div class="lb-trans"><p>ProKidney Corp.（納斯達克代碼：PROK - 獲取免費報告）週四下跌了 5.5%。該公司的股價最低跌至$2.15，最後交易價為$2.1550。在午盤交易中，共交易了 358,174 股，較平均交易量 973,694 股下降了 63%。該股票此前收盤價為$2.28。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities analysts recently commented on PROK shares. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of ProKidney in a report on Wednesday, October 8th. HC Wainwright started coverage on shares of ProKidney in a research report on Tuesday, December 16th. They set a &#34;buy&#34; rating and a $12.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of &#34;Hold&#34; and an average price target of $7.40.</p>
<div class="lb-trans"><p>一些股票分析師最近對 PROK 股票發表了評論。Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 ProKidney 的 “賣出（d-）” 評級。HC Wainwright 在 12 月 16 日星期二的研究報告中開始覆蓋 ProKidney 股票。他們對該股票設定了 “買入” 評級和$12.00 的目標價。四位分析師給予該股票 “買入” 評級，一位給予 “持有” 評級，兩位給予 “賣出” 評級。根據 MarketBeat 的數據，該股票的共識評級為 “持有”，平均目標價為$7.40。</p>
</div><p><strong>View Our Latest Stock Report on PROK</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 PROK 股票報告</strong></p>
</div><h2>ProKidney Stock Performance</h2>
<div class="lb-trans"><h2>ProKidney 股票表現</h2>
</div><p>The company's 50-day moving average price is $2.34 and its 200-day moving average price is $2.59. The firm has a market capitalization of $660.32 million, a PE ratio of -3.99 and a beta of 1.79.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均價格為$2.34，200 日移動平均價格為$2.59。該公司的市值為 6.6032 億美元，市盈率為-3.99，貝塔值為 1.79。</p>
</div><p>ProKidney (NASDAQ:PROK - Get Free Report) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). The business had revenue of $0.22 million during the quarter, compared to analysts' expectations of $0.04 million. As a group, analysts anticipate that ProKidney Corp. will post -0.57 earnings per share for the current year.</p>
<div class="lb-trans"><p>ProKidney（納斯達克代碼：PROK - 獲取免費報告）最近於 11 月 10 日星期一發布了季度財報。該公司報告季度每股收益為（$0.12），符合分析師的共識預期（$0.12）。該業務在季度內的收入為 22 萬美元，而分析師預期為 4 萬美元。整體來看，分析師預計 ProKidney Corp.在本年度將發佈每股收益為-0.57。</p>
</div><h2>Insider Activity at ProKidney</h2>
<div class="lb-trans"><h2>ProKidney 內部活動</h2>
</div><p>In related news, Director Brian Jg Pereira sold 502,136 shares of the business's stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $2.37, for a total value of $1,190,062.32. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 41.49% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Brian Jg Pereira 於 11 月 13 日星期四出售了 502,136 股該公司的股票。股票以平均價格$2.37 出售，總價值為$1,190,062.32。此次出售已在與證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站訪問。41.49% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On ProKidney</h2>
<div class="lb-trans"><h2>機構投資者對 ProKidney 的看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zullo Investment Group Inc. purchased a new stake in ProKidney in the 3rd quarter valued at $28,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of ProKidney during the second quarter worth about $36,000. AQR Capital Management LLC grew its holdings in shares of ProKidney by 106.4% during the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock worth $46,000 after buying an additional 27,098 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in ProKidney in the 3rd quarter valued at about $158,000. Finally, Virtu Financial LLC acquired a new stake in ProKidney during the 3rd quarter worth approximately $203,000. Hedge funds and other institutional investors own 51.59% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近增加或減少了對該公司的持股。Zullo Investment Group Inc.在第三季度購買了 ProKidney 的新股份，價值$28,000。Catalyst Funds Management Pty Ltd 在第二季度收購了 ProKidney 的新股份，價值約$36,000。AQR Capital Management LLC 在第一季度將其在 ProKidney 的持股增加了 106.4%。AQR Capital Management LLC 現在擁有 52,570 股該公司的股票，價值$46,000，此前在上個季度又購買了 27,098 股。Jefferies Financial Group Inc.在第三季度收購了 ProKidney 的新股份，價值約$158,000。最後，Virtu Financial LLC 在第三季度收購了 ProKidney 的新股份，價值約$203,000。對沖基金和其他機構投資者持有該公司 51.59% 的股票。</p>
</div><h2>About ProKidney</h2>
<div class="lb-trans"><h2>關於 ProKidney</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>ProKidney, Inc NASDAQ: PROK is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.</p>
<div class="lb-trans"><p>ProKidney, Inc.（納斯達克代碼：PROK）是一家臨牀階段的生物技術公司，專注於開發針對腎臟疾病的細胞治療。該公司的研究和開發活動集中在利用人源近端小管細胞來解決急性腎損傷（AKI）和慢性腎病（CKD）等疾病。通過針對腎臟損傷和功能障礙的基礎細胞機制，ProKidney 旨在提供超越當前支持性護理選項的新型再生醫學方法。</p>
</div><p>ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.</p>
<div class="lb-trans"><p>ProKidney 的主要項目利用專有方法分離和擴展腎上皮細胞，以創建可注射的治療產品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than ProKidney</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 ProKidney</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行命令 14330：特朗普最大的一次</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ProKidney Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 ProKidney 嗎？</h2>
</div><p>Before you consider ProKidney, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 ProKidney 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 ProKidney 並不在名單上。</p>
</div><p>While ProKidney currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 ProKidney 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

ProKidney (NASDAQ:PROK) 的股價下跌了 5.5% - 接下來會發生什麼？